<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859946</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0971</org_study_id>
    <secondary_id>NCI-2021-02784</secondary_id>
    <secondary_id>2020-0971</secondary_id>
    <nct_id>NCT04859946</nct_id>
  </id_info>
  <brief_title>Itacitinib for the Prevention of Graft Versus Host Disease</brief_title>
  <official_title>Itacitinib to Prevent Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies if itacitinib plus standard of care treatment may help prevent&#xD;
      graft-versus-host-disease (GVHD) in patients who have received an allogeneic (donor) stem&#xD;
      cell transplant. An allogeneic transplant uses blood-making cells from a family member or&#xD;
      unrelated donor to remove and replace a patient's abnormal blood cells. Sometimes the&#xD;
      transplanted cells from a donor can attack the body's normal cells (called graft-versus-host&#xD;
      disease). Giving itacitinib with standard of care treatment after the transplant may stop&#xD;
      this from happening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare the 100-day acute grade 2-4 GvHD rate to matched controls.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the 1-year rate of GvHD-free, relapse-free survival to matched controls.&#xD;
&#xD;
      II. To assess the time to neutrophil and platelet engraftment. III. To assess the toxicity&#xD;
      profile associated with this regimen. IV. To assess the incidence of severe grade 3-4 acute&#xD;
      GVHD. V. To assess the incidence of limited, extensive, and moderate to severe chronic GVHD.&#xD;
&#xD;
      VI. To assess the incidence of disease relapse. VII. To assess the incidence of non-relapse&#xD;
      mortality. VIII. To assess overall survival and progression-free survival. IX. To assess&#xD;
      immunosuppression discontinuation rate.&#xD;
&#xD;
      TERTIARY OBJECTIVE (CORRELATIVE STUDY):&#xD;
&#xD;
      I. Immune recovery and cytokines at various time points pre- and post- transplant&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING: Patients receive busulfan intravenously (IV) over 3 hours on days -20, -13, and&#xD;
      -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3.&#xD;
&#xD;
      STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients&#xD;
      also receive itacitinib orally (PO) once daily (QD) on days 5-60 in the absence of disease&#xD;
      progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients&#xD;
      also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby&#xD;
      patients then receive tacrolimus PO twice daily (BID).&#xD;
&#xD;
      After completion of study intervention, patients are followed up at days 100, 180, and 365&#xD;
      after stem cell transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute grade 2-4 graft versus host disease (GVHD)</measure>
    <time_frame>At 100 days after stem cell transplant</time_frame>
    <description>The 100-day acute grade 2-4 GvHD rate will be compared between groups using Fisher's exact test. Matched logistic regression techniques will also be considered for this endpoint. The proportion of patients with acute grade 2-4 GVHD at 100 days will be reported, along with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GVHD-free relapse-free survival</measure>
    <time_frame>From day of stem cell transplant to time of grade 3 or 4 acute GVHD or chronic GVHD needing systemic immunosuppression or relapse or death whichever occurs first, assessed at 1 year after stem cell transplant</time_frame>
    <description>Will be compared between groups using the log-rank test. The method of Kaplan and Meier will be used to estimate the distribution of GVHD-free, relapse-free survival. The estimated probability will be reported at 1 year along with a corresponding 95% confidence interval. In addition, Cox proportional hazards regression models will be fit to this endpoint, considering clinical, demographic, and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil and platelet engraftment</measure>
    <time_frame>Up to 365 days after stem cell transplant</time_frame>
    <description>Engraftment is defined as the presence of neutrophil recovery by day 28 post stem cell infusion. Neutrophil recovery is defined as a sustained absolute neutrophil count (ANC) &gt; 0.5 x 10^9/L for three consecutive days.&#xD;
Initial platelet recovery is defined as the first date of three consecutive laboratory values obtained for platelet count was &gt;= 20 x 10^9/L AND no platelet transfusions were administered for seven consecutive days immediately preceding this date. Will be calculated from the time of transplant and estimated by the Kaplan-Meier method. Distributions will be compared between patients with matched and mismatched donors via the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From day of stem cell transplant to day of death, assessed up to 365 days after stem cell transplant</time_frame>
    <description>Will be calculated from the time of transplant by the method of Kaplan and Meier. Cox proportional hazards regression analysis will be used to assess the association between these survival parameters and clinical and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From day of transplant to day of death or disease progression, assessed up to 365 days after stem cell transplant</time_frame>
    <description>Will be calculated from the time of transplant by the method of Kaplan and Meier. Cox proportional hazards regression analysis will be used to assess the association between these survival parameters and clinical and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>Up to 365 days after stem cell transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Up to 365 days after stem cell transplant</time_frame>
    <description>Defined as death from any cause other than relapse disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of limited, extensive, and moderate to severe chronic GVHD</measure>
    <time_frame>Up to 365 days after stem cell transplant</time_frame>
    <description>The cumulative incidence of acute and chronic GVHD with the competing risk of relapse and death without relapse will be estimated using the method of Gooley, and the method of Fine and Gray will be used to model the incidence by disease and clinical characteristics of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 365 days after stem cell transplant</time_frame>
    <description>Descriptive statistics will be used to summarize adverse events. Frequency counts and percentages will also be presented of subjects with serious adverse events and adverse events leading to withdrawal. All other safety parameters will be summarized using descriptive statistics or frequency counts. Graphical summaries will be used where appropriate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hematologic and Lymphocytic Disorder</condition>
  <arm_group>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3.&#xD;
STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0.&#xD;
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients also receive itacitinib PO QD on days 5-60 in the absence of disease progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby patients then receive tacrolimus PO BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo stem cell transplant</description>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <other_name>Allogeneic</other_name>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <other_name>INCB 039110</other_name>
    <other_name>INCB-039110</other_name>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Supportive care (itacitinib)</arm_group_label>
    <other_name>1,1'',1''''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N'', N''''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years to less than or equal to 70 years&#xD;
&#xD;
          -  Karnofsky performance status of at least 70&#xD;
&#xD;
          -  Patients with hematological disorders undergoing allogeneic stem cell transplant&#xD;
             (ASCT) with conditioning regimen of fractionated busulfan, thiotepa and fludarabine&#xD;
&#xD;
          -  Human leukocyte antigen (HLA)-identical sibling or at least 7/8 matched unrelated&#xD;
             donor, or a haploidentical related donor available&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks (3 months)&#xD;
&#xD;
          -  Direct bilirubin not greater than 1 mg/dL&#xD;
&#xD;
          -  Alanine transaminase (ALT) less than or equal 3 x upper limit of normal range&#xD;
&#xD;
          -  Creatinine clearance &gt;= 60 ml/ min&#xD;
&#xD;
          -  Diffusing capacity for carbon monoxide (DLCO) 50% of predicted corrected for&#xD;
             hemoglobin&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) of at least 50%&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of study drug. Post-menopausal women (defined as no&#xD;
             menses for at least 1 year) and surgically sterilized women are not required to&#xD;
             undergo a pregnancy test&#xD;
&#xD;
          -  Subjects (men and women) of childbearing potential must agree to use adequate&#xD;
             contraception beginning at the signing of the informed consent form (ICF) until at&#xD;
             least 30 days after the last dose of study drug. Recommended methods of birth control&#xD;
             are:&#xD;
&#xD;
               -  Hormonal contraception (birth control pills, patches, or rings)&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Birth control injections&#xD;
&#xD;
               -  Double barrier methods (diaphragm with spermicidal gel or condoms with birth&#xD;
                  control foam)&#xD;
&#xD;
               -  Sterilization of patient or partner (&quot;tubes tied&quot; or vasectomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with toxicities (Grade &gt; 1) unresolved from prior treatment (including&#xD;
             chemotherapy, targeted therapy, immunotherapy, experimental agents, radiation, or&#xD;
             surgery)&#xD;
&#xD;
          -  Active or clinically significant cardiac disease including:&#xD;
&#xD;
               -  Congestive heart failure - New York Heart Association (NYHA) &gt; class II&#xD;
&#xD;
               -  Active coronary artery disease&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or&#xD;
                  digoxin&#xD;
&#xD;
               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months&#xD;
                  before transplant, or myocardial infarction within 6 months before transplant&#xD;
&#xD;
          -  Patients with active hepatitis B and C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uday R Popat</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Uday R. Popat</last_name>
      <phone>713-745-3055</phone>
      <email>upopat@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Uday R. Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

